Open

Hormone Positive Breast Cancer Study for Premenopausal Patients

In this study, we want to compare the usual treatment for premenopausal women with hormone positive breast cancer to the usual treatment with the addition of chemotherapy. We are doing this study to see if adding chemotherapy improves survival and decreases the chances of the cancer coming back.

Age & Gender

18 years ~ 99 years
Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will have physical exams at different points throughout the study. You will take an "anti-estrogen" pill daily for 5 years and receive injections to suppress your ovaries; these are the usual treatments. You may or may not receive chemotherapy.

In-person visits:
1-36

Total length of participation:
15 years

Looking for Specific Volunteers

Able to participate:

You have hormone positive breast cancer
You are premenopausal
You are willing to receive chemotherapy
You have had surgery for your breast cancer
You have an Oncotype score less than 26 or are 'low-risk'

Not eligible if:

You have HER2 positive breast cancer
Your disease is metastatic
You are 'high-risk' or have an Oncotype score greater than or equal to 26
You have had breast cancer before
You are not willing to complete all of the required treatments

Contact the Team

Visit Location

Contact & Visit Location

Additional Study Information

Principal Investigator

JoEllen Speca
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

23-2618

ClinicalTrials.gov

NCT05879926

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.